RxDoctor Payments Data

Randi Kihnel, APRN

Adult Health · New Orleans, LANPI 1124655535

Payments from drug & device makers

$2,639in general payments, 2019–2025

Across 32 payments — averaging $82.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intera Oncology, Inc$875
  • AstraZeneca$495
  • Johnson & Johnson$294
  • AbbVie$241
  • Seagen Inc.$132
  • Janssen Scientific Affairs, LLC$125
  • plus $477 from 9 others

What the payments were for

  • Consulting fees$87533%
  • Food & beverage$1,66463%
  • Education$1004%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,639 in reported general payments places this provider in the 70th percentile of 203 adult health providers in Louisiana.

See all adult health providers in Louisiana

Medicare billing

Part B allowed, 2024
$30,845
Medicare patients
113
Services billed
435

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide16$216,809
CreonLipase/Protease/Amylase13$64,339
EliquisApixaban37$27,662
Abiraterone Acetate15$25,151
Ondansetron OdtOndansetron49$831
Oxycodone Hcl31$516
Lidocaine-PrilocaineLidocaine/Prilocaine38$506
Prochlorperazine Maleate40$442
Bicalutamide14$400
Pantoprazole Sodium25$382
Dexamethasone25$369
Olanzapine42$345
Ondansetron Hcl22$334
Mirtazapine12$289
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen12$196

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$241$64,33913 claims
PfizerEliquis$66$27,66237 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$125$25,15115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 203 adult health providers in Louisiana.

Other adult health in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →